Mylan Pharmaceuticals, Inc., has received final approval from the FDA for its Abbreviated New Drug Applications (ANDAs) for generic metformin HCl extended-release tablets, 500 and 750 mg. These tablets are the generic version of Bristol-Myers Squibb’s Canadian Glucophage XR Tablets. Metformin, a biguanide, is indicated for improvement of glucose control in patients with type-2 diabetes.

Random Posts:

• Fewer Menstrual Periods with New Oral Contraceptive
• Anticoagulant Reverses Side Effects
• Less Medication for Asthma?
• Docetaxel Combination For Head and Neck Cancer
• Generic Zantac Syrup For Reflux Disease and Ulcers